Cite
HARVARD Citation
Sigaud, R. et al. (n.d.). LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. Neuro-oncology. p. i93. [Online].